Hepatology Clinical

ABSTRACT

Compared with conventional practice, ROTEM-guided blood product transfusion resulted in fewer units of platelets (0.22 I vs i 0.66 units per patient, I P i = 0.32) and cryoprecipitate (0.61 I vs i 1.24 units/patient, I P i = 0.26) per patient. Twelve patients used one drug, one patient used two drugs, four patients used three drugs, two patients used four drugs, and one patient used five drugs. B 19 b B Non-cirrhotic, non-hepatitis hepatocellular carcinoma A case report b B M Gururatsakul b I Department of Gastroenterology and Hepatology, Chulabhorn Hospital, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand;i I Department of Gastroenterology and Hepatology, Cairns Hospital, Cairns, Queensland, Australia i B I Introduction: i b Hepatocellular carcinoma (HCC) generally develops in patients with underlying chronic liver disease, cirrhosis, chronic hepatitis B or chronic hepatitis C virus infections, or non-alcohol-associated steatohepatitis. We aimed to assess COVID-19 vaccination rates in patients with liver disease, comparing them with the general population, to identify if this was a vulnerable patient group who needed particular follow-up. B I Methods: i b We performed a cross-sectional study, collecting COVID-19 vaccination data from patients who had attended an outpatient liver clinic between 1 July 2021 and 30 September 2021. [Extracted from the article] Copyright of Journal of Gastroenterology & Hepatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)